Review



c neoformans atcc 32609  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    ATCC c neoformans atcc 32609
    C Neoformans Atcc 32609, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 64 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c neoformans atcc 32609/product/ATCC
    Average 94 stars, based on 64 article reviews
    c neoformans atcc 32609 - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    c neoformans atcc 32609  (ATCC)
    94
    ATCC c neoformans atcc 32609
    C Neoformans Atcc 32609, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c neoformans atcc 32609/product/ATCC
    Average 94 stars, based on 1 article reviews
    c neoformans atcc 32609 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    c neoformans atcc  (ATCC)
    94
    ATCC c neoformans atcc
    MICs of NT-a9 against common pathogenic fungi
    C Neoformans Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c neoformans atcc/product/ATCC
    Average 94 stars, based on 1 article reviews
    c neoformans atcc - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    MICs of NT-a9 against common pathogenic fungi

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans In Vitro and In Vivo

    doi: 10.1128/AAC.01628-19

    Figure Lengend Snippet: MICs of NT-a9 against common pathogenic fungi

    Article Snippet: Therefore, we further evaluated the in vivo effects of NT-a9 against C. neoformans . table ft1 table-wrap mode="anchored" t5 TABLE 2 caption a7 Species a Strain Value (μg/ml) for b : NT-a9 ISA FLC AMB MIC MIC 50 MIC MIC 50 MIC MIC 50 MIC C. neoformans H99 0.031 0.004 0.13 0.031 4 2 1 C. neoformans ATCC 32609 0.016 0.008 0.016 0.004 0.5 0.13 0.13 C. neoformans SCZ50100 0.008 0.002 0.063 0.016 4 2 1 C. neoformans SCZ50101 0.002 0.002 0.031 0.004 4 1 0.5 C. neoformans SCZ50102 0.008 0.004 0.063 0.031 8 4 1 C. neoformans SCZ50104 0.008 0.002 0.063 0.016 4 2 1 C. neoformans SCZ50106 0.008 0.002 0.063 0.031 8 4 1 C. neoformans SCZ50107 0.008 0.002 0.063 0.031 8 4 1 C. neoformans HN2-40 0.063 0.031 0.13 0.063 4 2 2 C. neoformans HN15 0.25 0.25 0.063 0.063 2 1 4 C. neoformans HN17 0.063 0.063 0.063 0.063 4 2 1 C. neoformans HN19 0.063 0.063 0.063 0.031 4 2 1 C. neoformans HN20 0.063 0.063 0.13 0.063 4 2 2 C. neoformans BJ3 0.063 0.063 0.13 0.008 4 0.13 2 C. neoformans BJ72 0.063 0.063 0.13 0.031 4 1 2 C. neoformans BJ95 0.063 0.063 0.13 0.008 4 0.5 2 C. neoformans SH68 0.063 0.063 0.13 0.008 4 0.13 1 C. gattii WM178 0.13 0.063 0.13 0.063 8 4 1 C. gattii WM179 0.063 0.016 0.13 0.016 4 2 2 C. gattii E566 0.063 0.063 0.13 0.031 4 2 2 C. gattii SCZ20024 0.13 0.063 0.13 0.031 4 1 4 C. gattii SCZ20031 0.063 0.063 0.13 0.031 4 1 2 C. albicans SC5314 0.13 0.063 0.13 0.031 0.5 0.13 0.13 C. albicans 333 0.25 0.13 0.13 0.031 1 0.25 0.25 C. krusei 463 1 0.13 0.13 0.063 4 1 0.5 C. krusei 397 0.13 0.063 0.13 0.063 2 1 1 C. krusei 467 0.13 0.13 0.13 0.13 0.5 0.25 0.25 C. tropicalis ATCC 750 0.25 0.13 0.5 0.13 2 1 0.5 C. tropicalis 112936 0.25 0.13 1 0.13 2 0.5 0.5 C. glabrata ATCC 2001 0.13 0.063 0.13 0.063 2 1 1 C. glabrata 537 0.13 0.063 0.13 0.063 0.5 0.25 0.5 C. parapsilosis 9018 0.13 0.063 0.13 0.063 0.25 0.13 0.13 Open in a separate window a Cryptococcus species: C. neoformans and C. gattii .

    Techniques:

    Time-kill curves of C. neoformans strain H99 (A) and C. albicans strain SC5314 (B) treated with NT-a9 or fluconazole (FLC). Strains were grown in RPMI 1640 medium with a starting inoculum of 5 × 105 CFU/ml. Aliquots were obtained at the predetermined time points, and serial dilutions were spread on SDA plates. Colony counts were determined after incubation. The results are calculated from two independent experiments.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans In Vitro and In Vivo

    doi: 10.1128/AAC.01628-19

    Figure Lengend Snippet: Time-kill curves of C. neoformans strain H99 (A) and C. albicans strain SC5314 (B) treated with NT-a9 or fluconazole (FLC). Strains were grown in RPMI 1640 medium with a starting inoculum of 5 × 105 CFU/ml. Aliquots were obtained at the predetermined time points, and serial dilutions were spread on SDA plates. Colony counts were determined after incubation. The results are calculated from two independent experiments.

    Article Snippet: Therefore, we further evaluated the in vivo effects of NT-a9 against C. neoformans . table ft1 table-wrap mode="anchored" t5 TABLE 2 caption a7 Species a Strain Value (μg/ml) for b : NT-a9 ISA FLC AMB MIC MIC 50 MIC MIC 50 MIC MIC 50 MIC C. neoformans H99 0.031 0.004 0.13 0.031 4 2 1 C. neoformans ATCC 32609 0.016 0.008 0.016 0.004 0.5 0.13 0.13 C. neoformans SCZ50100 0.008 0.002 0.063 0.016 4 2 1 C. neoformans SCZ50101 0.002 0.002 0.031 0.004 4 1 0.5 C. neoformans SCZ50102 0.008 0.004 0.063 0.031 8 4 1 C. neoformans SCZ50104 0.008 0.002 0.063 0.016 4 2 1 C. neoformans SCZ50106 0.008 0.002 0.063 0.031 8 4 1 C. neoformans SCZ50107 0.008 0.002 0.063 0.031 8 4 1 C. neoformans HN2-40 0.063 0.031 0.13 0.063 4 2 2 C. neoformans HN15 0.25 0.25 0.063 0.063 2 1 4 C. neoformans HN17 0.063 0.063 0.063 0.063 4 2 1 C. neoformans HN19 0.063 0.063 0.063 0.031 4 2 1 C. neoformans HN20 0.063 0.063 0.13 0.063 4 2 2 C. neoformans BJ3 0.063 0.063 0.13 0.008 4 0.13 2 C. neoformans BJ72 0.063 0.063 0.13 0.031 4 1 2 C. neoformans BJ95 0.063 0.063 0.13 0.008 4 0.5 2 C. neoformans SH68 0.063 0.063 0.13 0.008 4 0.13 1 C. gattii WM178 0.13 0.063 0.13 0.063 8 4 1 C. gattii WM179 0.063 0.016 0.13 0.016 4 2 2 C. gattii E566 0.063 0.063 0.13 0.031 4 2 2 C. gattii SCZ20024 0.13 0.063 0.13 0.031 4 1 4 C. gattii SCZ20031 0.063 0.063 0.13 0.031 4 1 2 C. albicans SC5314 0.13 0.063 0.13 0.031 0.5 0.13 0.13 C. albicans 333 0.25 0.13 0.13 0.031 1 0.25 0.25 C. krusei 463 1 0.13 0.13 0.063 4 1 0.5 C. krusei 397 0.13 0.063 0.13 0.063 2 1 1 C. krusei 467 0.13 0.13 0.13 0.13 0.5 0.25 0.25 C. tropicalis ATCC 750 0.25 0.13 0.5 0.13 2 1 0.5 C. tropicalis 112936 0.25 0.13 1 0.13 2 0.5 0.5 C. glabrata ATCC 2001 0.13 0.063 0.13 0.063 2 1 1 C. glabrata 537 0.13 0.063 0.13 0.063 0.5 0.25 0.5 C. parapsilosis 9018 0.13 0.063 0.13 0.063 0.25 0.13 0.13 Open in a separate window a Cryptococcus species: C. neoformans and C. gattii .

    Techniques: Incubation

    Sterol analysis of C. neoformans cells by GC-MS. C. neoformans H99 was treated with NT-a9 or fluconazole (FLC) for 8 h. Cells were collected, and total sterols were extracted. Sterol compositions were analyzed by GC-MS. Data are shown as the mean values ± standard deviations from two independent experiments.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans In Vitro and In Vivo

    doi: 10.1128/AAC.01628-19

    Figure Lengend Snippet: Sterol analysis of C. neoformans cells by GC-MS. C. neoformans H99 was treated with NT-a9 or fluconazole (FLC) for 8 h. Cells were collected, and total sterols were extracted. Sterol compositions were analyzed by GC-MS. Data are shown as the mean values ± standard deviations from two independent experiments.

    Article Snippet: Therefore, we further evaluated the in vivo effects of NT-a9 against C. neoformans . table ft1 table-wrap mode="anchored" t5 TABLE 2 caption a7 Species a Strain Value (μg/ml) for b : NT-a9 ISA FLC AMB MIC MIC 50 MIC MIC 50 MIC MIC 50 MIC C. neoformans H99 0.031 0.004 0.13 0.031 4 2 1 C. neoformans ATCC 32609 0.016 0.008 0.016 0.004 0.5 0.13 0.13 C. neoformans SCZ50100 0.008 0.002 0.063 0.016 4 2 1 C. neoformans SCZ50101 0.002 0.002 0.031 0.004 4 1 0.5 C. neoformans SCZ50102 0.008 0.004 0.063 0.031 8 4 1 C. neoformans SCZ50104 0.008 0.002 0.063 0.016 4 2 1 C. neoformans SCZ50106 0.008 0.002 0.063 0.031 8 4 1 C. neoformans SCZ50107 0.008 0.002 0.063 0.031 8 4 1 C. neoformans HN2-40 0.063 0.031 0.13 0.063 4 2 2 C. neoformans HN15 0.25 0.25 0.063 0.063 2 1 4 C. neoformans HN17 0.063 0.063 0.063 0.063 4 2 1 C. neoformans HN19 0.063 0.063 0.063 0.031 4 2 1 C. neoformans HN20 0.063 0.063 0.13 0.063 4 2 2 C. neoformans BJ3 0.063 0.063 0.13 0.008 4 0.13 2 C. neoformans BJ72 0.063 0.063 0.13 0.031 4 1 2 C. neoformans BJ95 0.063 0.063 0.13 0.008 4 0.5 2 C. neoformans SH68 0.063 0.063 0.13 0.008 4 0.13 1 C. gattii WM178 0.13 0.063 0.13 0.063 8 4 1 C. gattii WM179 0.063 0.016 0.13 0.016 4 2 2 C. gattii E566 0.063 0.063 0.13 0.031 4 2 2 C. gattii SCZ20024 0.13 0.063 0.13 0.031 4 1 4 C. gattii SCZ20031 0.063 0.063 0.13 0.031 4 1 2 C. albicans SC5314 0.13 0.063 0.13 0.031 0.5 0.13 0.13 C. albicans 333 0.25 0.13 0.13 0.031 1 0.25 0.25 C. krusei 463 1 0.13 0.13 0.063 4 1 0.5 C. krusei 397 0.13 0.063 0.13 0.063 2 1 1 C. krusei 467 0.13 0.13 0.13 0.13 0.5 0.25 0.25 C. tropicalis ATCC 750 0.25 0.13 0.5 0.13 2 1 0.5 C. tropicalis 112936 0.25 0.13 1 0.13 2 0.5 0.5 C. glabrata ATCC 2001 0.13 0.063 0.13 0.063 2 1 1 C. glabrata 537 0.13 0.063 0.13 0.063 0.5 0.25 0.5 C. parapsilosis 9018 0.13 0.063 0.13 0.063 0.25 0.13 0.13 Open in a separate window a Cryptococcus species: C. neoformans and C. gattii .

    Techniques: Gas Chromatography-Mass Spectrometry

    Survival curves for mice with disseminated cryptococcosis treated with antifungal agents. Mice were inoculated intravenously with C. neoformans H99 at 1.8 × 106 CFU per animal and then treated with NT-a9, isavuconazole (ISA), fluconazole (FLC), or amphotericin B (AMB) (n = 10 mice per group). The differences in in vivo effects between high doses (A) and low doses (B) of NT-a9 were investigated. Antifungal monotherapy was initiated 2 h after inoculation and continued for 7 days. Mice were monitored without therapy until day 20. Amphotericin B was administered intraperitoneally, while other antifungal treatments were performed through oral gavage. ***, P < 0.001 versus the results for the control. One representative result out of two independent experiments is shown.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans In Vitro and In Vivo

    doi: 10.1128/AAC.01628-19

    Figure Lengend Snippet: Survival curves for mice with disseminated cryptococcosis treated with antifungal agents. Mice were inoculated intravenously with C. neoformans H99 at 1.8 × 106 CFU per animal and then treated with NT-a9, isavuconazole (ISA), fluconazole (FLC), or amphotericin B (AMB) (n = 10 mice per group). The differences in in vivo effects between high doses (A) and low doses (B) of NT-a9 were investigated. Antifungal monotherapy was initiated 2 h after inoculation and continued for 7 days. Mice were monitored without therapy until day 20. Amphotericin B was administered intraperitoneally, while other antifungal treatments were performed through oral gavage. ***, P < 0.001 versus the results for the control. One representative result out of two independent experiments is shown.

    Article Snippet: Therefore, we further evaluated the in vivo effects of NT-a9 against C. neoformans . table ft1 table-wrap mode="anchored" t5 TABLE 2 caption a7 Species a Strain Value (μg/ml) for b : NT-a9 ISA FLC AMB MIC MIC 50 MIC MIC 50 MIC MIC 50 MIC C. neoformans H99 0.031 0.004 0.13 0.031 4 2 1 C. neoformans ATCC 32609 0.016 0.008 0.016 0.004 0.5 0.13 0.13 C. neoformans SCZ50100 0.008 0.002 0.063 0.016 4 2 1 C. neoformans SCZ50101 0.002 0.002 0.031 0.004 4 1 0.5 C. neoformans SCZ50102 0.008 0.004 0.063 0.031 8 4 1 C. neoformans SCZ50104 0.008 0.002 0.063 0.016 4 2 1 C. neoformans SCZ50106 0.008 0.002 0.063 0.031 8 4 1 C. neoformans SCZ50107 0.008 0.002 0.063 0.031 8 4 1 C. neoformans HN2-40 0.063 0.031 0.13 0.063 4 2 2 C. neoformans HN15 0.25 0.25 0.063 0.063 2 1 4 C. neoformans HN17 0.063 0.063 0.063 0.063 4 2 1 C. neoformans HN19 0.063 0.063 0.063 0.031 4 2 1 C. neoformans HN20 0.063 0.063 0.13 0.063 4 2 2 C. neoformans BJ3 0.063 0.063 0.13 0.008 4 0.13 2 C. neoformans BJ72 0.063 0.063 0.13 0.031 4 1 2 C. neoformans BJ95 0.063 0.063 0.13 0.008 4 0.5 2 C. neoformans SH68 0.063 0.063 0.13 0.008 4 0.13 1 C. gattii WM178 0.13 0.063 0.13 0.063 8 4 1 C. gattii WM179 0.063 0.016 0.13 0.016 4 2 2 C. gattii E566 0.063 0.063 0.13 0.031 4 2 2 C. gattii SCZ20024 0.13 0.063 0.13 0.031 4 1 4 C. gattii SCZ20031 0.063 0.063 0.13 0.031 4 1 2 C. albicans SC5314 0.13 0.063 0.13 0.031 0.5 0.13 0.13 C. albicans 333 0.25 0.13 0.13 0.031 1 0.25 0.25 C. krusei 463 1 0.13 0.13 0.063 4 1 0.5 C. krusei 397 0.13 0.063 0.13 0.063 2 1 1 C. krusei 467 0.13 0.13 0.13 0.13 0.5 0.25 0.25 C. tropicalis ATCC 750 0.25 0.13 0.5 0.13 2 1 0.5 C. tropicalis 112936 0.25 0.13 1 0.13 2 0.5 0.5 C. glabrata ATCC 2001 0.13 0.063 0.13 0.063 2 1 1 C. glabrata 537 0.13 0.063 0.13 0.063 0.5 0.25 0.5 C. parapsilosis 9018 0.13 0.063 0.13 0.063 0.25 0.13 0.13 Open in a separate window a Cryptococcus species: C. neoformans and C. gattii .

    Techniques: In Vivo, Control

    Fungal burdens in mice with disseminated cryptococcosis treated with antifungal agents. Mice were inoculated intravenously with C. neoformans H99 at 1.8 × 106 CFU per animal and treated with NT-a9, fluconazole, or amphotericin B (n = 10 mice per group). Antifungal monotherapy was initiated 1 day after inoculation and continued for 3 days. Mice were humanely euthanized 1 day after the last treatment, and brain (A) and lung (B) samples were collected for fungal burden analysis. Amphotericin B was administered intraperitoneally, while other treatments were performed through oral gavage. Horizontal lines represent mean values, and whiskers represent standard deviations. ***, P < 0.001 versus the result for the control. One representative result out of two independent experiments is shown.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans In Vitro and In Vivo

    doi: 10.1128/AAC.01628-19

    Figure Lengend Snippet: Fungal burdens in mice with disseminated cryptococcosis treated with antifungal agents. Mice were inoculated intravenously with C. neoformans H99 at 1.8 × 106 CFU per animal and treated with NT-a9, fluconazole, or amphotericin B (n = 10 mice per group). Antifungal monotherapy was initiated 1 day after inoculation and continued for 3 days. Mice were humanely euthanized 1 day after the last treatment, and brain (A) and lung (B) samples were collected for fungal burden analysis. Amphotericin B was administered intraperitoneally, while other treatments were performed through oral gavage. Horizontal lines represent mean values, and whiskers represent standard deviations. ***, P < 0.001 versus the result for the control. One representative result out of two independent experiments is shown.

    Article Snippet: Therefore, we further evaluated the in vivo effects of NT-a9 against C. neoformans . table ft1 table-wrap mode="anchored" t5 TABLE 2 caption a7 Species a Strain Value (μg/ml) for b : NT-a9 ISA FLC AMB MIC MIC 50 MIC MIC 50 MIC MIC 50 MIC C. neoformans H99 0.031 0.004 0.13 0.031 4 2 1 C. neoformans ATCC 32609 0.016 0.008 0.016 0.004 0.5 0.13 0.13 C. neoformans SCZ50100 0.008 0.002 0.063 0.016 4 2 1 C. neoformans SCZ50101 0.002 0.002 0.031 0.004 4 1 0.5 C. neoformans SCZ50102 0.008 0.004 0.063 0.031 8 4 1 C. neoformans SCZ50104 0.008 0.002 0.063 0.016 4 2 1 C. neoformans SCZ50106 0.008 0.002 0.063 0.031 8 4 1 C. neoformans SCZ50107 0.008 0.002 0.063 0.031 8 4 1 C. neoformans HN2-40 0.063 0.031 0.13 0.063 4 2 2 C. neoformans HN15 0.25 0.25 0.063 0.063 2 1 4 C. neoformans HN17 0.063 0.063 0.063 0.063 4 2 1 C. neoformans HN19 0.063 0.063 0.063 0.031 4 2 1 C. neoformans HN20 0.063 0.063 0.13 0.063 4 2 2 C. neoformans BJ3 0.063 0.063 0.13 0.008 4 0.13 2 C. neoformans BJ72 0.063 0.063 0.13 0.031 4 1 2 C. neoformans BJ95 0.063 0.063 0.13 0.008 4 0.5 2 C. neoformans SH68 0.063 0.063 0.13 0.008 4 0.13 1 C. gattii WM178 0.13 0.063 0.13 0.063 8 4 1 C. gattii WM179 0.063 0.016 0.13 0.016 4 2 2 C. gattii E566 0.063 0.063 0.13 0.031 4 2 2 C. gattii SCZ20024 0.13 0.063 0.13 0.031 4 1 4 C. gattii SCZ20031 0.063 0.063 0.13 0.031 4 1 2 C. albicans SC5314 0.13 0.063 0.13 0.031 0.5 0.13 0.13 C. albicans 333 0.25 0.13 0.13 0.031 1 0.25 0.25 C. krusei 463 1 0.13 0.13 0.063 4 1 0.5 C. krusei 397 0.13 0.063 0.13 0.063 2 1 1 C. krusei 467 0.13 0.13 0.13 0.13 0.5 0.25 0.25 C. tropicalis ATCC 750 0.25 0.13 0.5 0.13 2 1 0.5 C. tropicalis 112936 0.25 0.13 1 0.13 2 0.5 0.5 C. glabrata ATCC 2001 0.13 0.063 0.13 0.063 2 1 1 C. glabrata 537 0.13 0.063 0.13 0.063 0.5 0.25 0.5 C. parapsilosis 9018 0.13 0.063 0.13 0.063 0.25 0.13 0.13 Open in a separate window a Cryptococcus species: C. neoformans and C. gattii .

    Techniques: Control